Influencia del tratamiento biológico en los factores de riesgo cardiovascular de los pacientes con enfermedad inflamatoria intestinal

Abstract

IntroductionChronic immune-mediated diseases, including inflammatory bowel disease (IBD), present an increased risk of developing early atherosclerosis and cardiovascular events (CVE) at early age. ObjectiveTo describe the baseline and 1-year cardiovascular profile of patients with IBD according to the biologic treatment received, taking into account the inflammatory activity. Patients and methodsIt is a retrospective, observational study that included 374 patients. Cardiovascular risk factors (CVRF) and CVE were collected at the baseline visit and at one-year follow-up to describe the cardiovascular risk according to the biological treatment received, also assessing clinical and biological remission. ResultsA total of 374 patients were included: 146 (38.73%) were treated with Infliximab, 128 (33.95%) with adalimumab, 61 (16.18%) with ustekinumab and 42 (11.14%) with vedolizumab.The changes in blood glucose levels are [86.31mg/dL (84.57–88.06) vs. 89.25mg/dL (87.54–90.96), P=.001] for those treated with antiTNFα and [86.52mg/dL (83.48–89.55) vs. 89.44mg/dL (85.77–93.11), P=.11] in the other group.In the group treated with antiTNFα total cholesterol values at baseline visit are [169.40mg/dL (164.97–173.83) vs. 177.40mg/dL (172.75–182.05) at one year of treatment, P=<.001], those of HDL [50.22mg/dL (48.39–52.04) vs. 54.26mg/dL (52.46–56.07), P=<.001] and those of triglycerides [114.77mg/dL (106.36–123.18) vs. 121.83mg/dL (112.11–131.54), P=.054].Regarding weight, an increase was observed, both in those patients treated with antiTNFα [71.39kg (69.53–73.25) vs. 72.87kg (71.05–74.70), P<.001], and in the group treated with ustekinumab and vedolizumab [67.59kg (64.10–71.08) vs. 69.43kg (65.65–73.04), P=.003].Concerning CVE, no significant differences were observed neither according to the drug used (p=0.36), nor according to personal history of CVE (P=.23) nor according to inflammatory activity (P=.46). ConclusionsOur results on a real cohort of patients with IBD treated with biologic drugs show a better control of certain cardiovascular parameters such as CRP or HDL, but a worsening of others such as total cholesterol or triglycerides, regardless of the treatment. Therefore, it is possibly the disease control and not the therapeutic target used, the one that affect the cardiovascular risk of these patients.